All In Biotech

Drug Trial Radar · NCT05518045

A Study of LM-108 as Monotherapy or in Combination With Antitumor Therapies in Subjects With Advanced Solid Tumors

An Open-Label, Dose-Escalation and Dose-Expansion Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of LM-108 for Injection as Monotherapy or in Combination With Antitumor Therapies in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

392

Planned (sponsor's estimate)

Start

Aug 26, 2022

Primary completion

Oct 31, 2026

Study completion Oct 31, 2026

Sponsor

Lead sponsor
LaNova Medicines LimitedIndustry
Sponsor type
Industry
First posted
Aug 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase I/II, Open-Label, Dose-Escalation and Dose-Expansion Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile and Preliminary Efficacy of LM-108, an Anti-CCR8 Monoclonal Antibody, as Monotherapy or in Combination with Antitumor Therapies in Patients with Advanced Solid Tumors

Conditions

  • Advanced Solid Tumor

Interventions

  • LM-108Drug

    Administered intravenously

  • ToripalimabDrug

    Administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I Dose Escalation:Incidence of adverse events (AEs)Time frame: 152 Weeks
  2. Phase I Dose Escalation:Incidence of dose-limiting toxicity (DLT)Time frame: 152 Weeks
  3. Phase I Dose Escalation:Incidence of serious adverse event (SAE)Time frame: 152 Weeks
  4. Phase I Dose Escalation:Incidence of clinical significant in laboratory examinations, including hematology, urinalysis, blood biochemistry, coagulation tests and thyroid function.Time frame: 152 Weeks
  5. Phase II Dose Expansion Cohort:Objective Response Rate (ORR) Evaluated by Researchers Based on RECIST v1.1Time frame: 152 Weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.